Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Quantum BioPharma Ltd. (QNTM)

Compare
6.30
+0.06
+(0.98%)
As of 10:00:41 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Zeeshan Saeed Founder, CEO, President & Executive Co-Chairman 218.63k -- 1970
Mr. Anthony John Durkacz Founder & Executive Co-Chairman 218.63k -- 1976
Mr. Donal Carroll CPA Chief Financial Officer 218.63k -- 1977
Mr. Nathan Coyle CPA Controller 93.97k -- 1981
Dr. Lakshmi P. Kotra BPHARM, Ph.D. CEO of Lucid & Director -- -- 1971
Dr. Andrzej Chruscinski M.D., Ph.D. Vice President of Clinical & Scientific Affairs 178.21k -- --
Dr. Ashwini Joshi Director of Pharmaceutical Development 89.4k -- --
Mr. Jason D. Sawyer Head of Finance & Mergers and Acquisitions -- -- --
Ms. Maryann Adesso Corporate Secretary -- -- --
Randell Mack President of FSD BioSciences -- -- --

Quantum BioPharma Ltd.

55 University Ave.
Suite 1003
Toronto, ON M5J 2H7
Canada
https://www.quantumbiopharma.com
Sector: 
Healthcare

Description

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

Corporate Governance

Quantum BioPharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 12, 2025 at 8:00 PM UTC - May 16, 2025 at 8:00 PM UTC

Quantum BioPharma Ltd. Earnings Date

Recent Events

April 14, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

April 10, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

April 3, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

April 1, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 31, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 28, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 27, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 26, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

March 20, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

February 11, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

Related Tickers